Taiho Pharma Oceania Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
5 result(s) found, displaying 1 to 5
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LYTGOBI futibatinib 4 mg tablet blister pack.
-
Apr-2024Prescription medicine evaluationActive ingredient: futibatinib.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for INQOVI 35/100 decitabine 35 mg and cedazuridine 100 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for INQOVI 35/100 decitabine 35 mg and cedazuridine 100 mg tablet bottle.
-
Prescription medicine decision summaryTGA decision: Inqovi 35/100 (decitabine and cedazuridine) is approved to treat adult patients with myelodysplastic syndromes and CMML.